Domenica Rubino
Endocrinology, Diabetes & Metabolism · Arlington, VANPI 1639226236
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 49.2% of the total. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 543 payments — averaging $1120.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$299K
- Novo Nordisk AS$179K
- Boehringer Ingelheim$27K
- Boehringer Ingelheim International GmbH$23K
- AbbVie$18K
- Regeneron$16K
- plus $45K from 14 others
Across 872 payments — averaging $2700.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1.6M
- Boehringer Ingelheim$407K
- Amgen$185K
- AstraZeneca$164K
- Boehringer Ingelheim International GmbH$17K
- Boehringer Ingelheim France S.a.s.$13K
What the payments were for
- Consulting fees$288,50547%
- Speaking & faculty fees$135,12122%
- Travel & lodging$168,20628%
- Food & beverage$14,9662%
- Education$1,6840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 280 | $299,248 |
| Novo Nordisk AS | 97 | $179,231 |
| Boehringer Ingelheim | 39 | $27,062 |
| Boehringer Ingelheim International GmbH | 18 | $23,334 |
| AbbVie | 16 | $18,047 |
| Regeneron | 35 | $16,116 |
| Neurocrine Biosciences, Inc. | 9 | $12,867 |
| Lilly USA, LLC | 16 | $11,420 |
| AstraZeneca | 5 | $9,765 |
| Shionogi Inc | 3 | $3,360 |
| Ferring Pharmaceuticals AS | 1 | $3,210 |
| Eli Lilly | 8 | $2,024 |
| Novo Nordisk Health Care AG | 1 | $1,700 |
| F. Hoffmann-la Roche AG | 1 | $500 |
| Pfizer | 1 | $400 |
| IBSA Pharma Inc. | 4 | $81 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Corcept Therapeutics | 2 | $45 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kvk-tech, Inc. | 4 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$608,482 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 55 | $67,743 |
| OzempicSemaglutide | 20 | $32,790 |
| Metformin Hcl ErMetformin Hcl | 19 | $449 |
| Rosuvastatin Calcium | 13 | $119 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 12 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $11,420 | $67,74355 claims |
| Novo NordiskOzempic | $299,248 | $32,79020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Arlington
- Caroline HuangArlington$30K
- Thien-Giang Bach-HuynhArlington$8K
- Massoud SaberiniaArlington$8K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.